0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial

RICHARD I. FISHER, M.D.; CHARLES A. COLTMAN Jr., M.D.; JAMES H. DOROSHOW, M.D.; ANTHONY A. RAYNER, M.D.; MICHAEL J. HAWKINS, M.D.; JAMES W. MIER, M.D.; PETER WIERNIK, M.D.; JOHN D. MCMANNIS, Ph.D.; GEOFFREY R. WEISS, M.D.; KIM A. MARGOLIN, M.D.; BRETT T. GEMLO, M.D.; DANIEL F. HOTH, M.D.; DAVID R. PARKINSON, M.D.; and ELISABETH PAIETTA, Ph.D.
[+] Article and Author Information

▸Requests for reprints should be addressed to Richard I. Fisher, M.D.; Section of Hematology/Oncology, Loyola University Medical Center, 2160 South First Avenue; Maywood, IL 60153.


Maywood, Illinois; San Antonio, Texas; Duarte and San Francisco, California; Bethesda, Maryland; Boston, Massachusetts; and New York, New York


© 1988 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1988;108(4):518-523. doi:10.7326/0003-4819-108-4-518
Text Size: A A A

Study Objective: To confirm the antitumor efficacy of treatment with interleukin-2 and lymphokine-activated killer cells in patients with metastatic renal cancer.

Design: Nonrandomized, phase II clinical trial.

Setting: Tertiary care units in university medical centers.

Patients: Consecutive trial of 35 patients with metastatic or unresectable renal cell cancer who have bidimensionally measurable disease, performance status 0 or 1, and normal function of all vital organs. Thirty-two patients completed interkeukin-2 priming and received at least one lymphokine-activated killer cell infusion. Three patients were removed from the study and did not receive infusion of cells secondary to rapid tumor progression or toxicity.

Interventions: Patients initially received recombinant interleukin-2, 100 000 units/kg body weight every 8 hours, on days 1 to 5 in a priming phase to stimulate lymphokine-activated killer cell precursors and effector activity in vivo. Leukapheresis was done on days 8 to 12 and lymphocytes were cultured in vitro with interleukin-2 for 3 to 4 days to amplify lymphokine-activated killer cell activity. Finally, interleukin-2, 100 000 units/kg every 8 hours, was infused with cultured cells on days 12 to 16. All doses of interleukin-2 and lymphokine-activated killer cells were administered in intensive care units.

Measurements and Main Results: The mean number of doses of interleukin-2 administered during the priming phase was 12.9 ± 0.4; the mean number of lymphokine-activated killer cells reinfused was 7.0 ± 0.6 X 1010; and the mean number of interleukin-2 doses administered during the last phase was 10.2 ± 0.6. The overall objective response rate was 16%; two patients had complete responses and three patients had partial responses with greater than 50% reduction of all measurable tumor. The complete responders remain disease-free at 12 and 9 months. Two partial responders have not had tumor regrowth at 16 and 15 months. The third partial responder relapsed at 4 months. Toxicity was severe but generally of short duration and manageable. There were no treatment-related deaths. Hypotension, weight gain, anemia, and elevations of serum creatinine levels and liver enzymes were common. Two patients required intubation; one patient had a myocardial infarction.

Conclusions: This phase II study confirms the antitumor activity of interleukin-2 and lymphokine-activated killer cell therapy in patients with metastatic or unresectable renal cell cancer. Response rates, especially complete remission rates, are comparable or better than rates achieved with other forms of therapy.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)